Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, announced the pricing of senior unsecured notes in an aggregate principal amount of US$3.5 billion, in an underwritten, registered public offering, consisting of US$750 million of 4.80% senior notes maturing in 2029, US$1 billion of 5.10% senior notes maturing in 2035, US$1 billion of 5.50% senior notes maturing in 2054, and US$750 million of 5.60% senior notes maturing in 2064. The offering closed on November 20, 2024.

Latham & Watkins LLP represented the underwriters in the offering with a corporate team led by New York/Los Angeles partner Greg Rodgers and Washington, D.C./New York partner Chuck Cassidy, with associates Karysa Norris and Steve Hess. Advice was also provided on tax matters by New York partner Bora Bozkurt; on healthcare matters by Bay Area partner Betty Pang; on intellectual property matters by San Diego/Bay Area partner Christopher Hazuka, with associates Robert Yeh and Patrick Chew; on data privacy matters by Heather Deixler, with associate Kiara Vaughn; on FDA regulatory matters by Washington, D.C. partner Ben Haas and Washington, D.C. counsel Chad Jennings, with associate Meryl Bartlett; on sanctions matters by Washington, D.C. counsel Ruchi Gill, with associate Elliot Hecht; on EU/UK regulatory matters by Paris/Brussels partner Eveline Van Keymeulen, with associate Jeanne Fabre; and on anti-corruption matters by Washington, D.C. partner Kevin Chambers.